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Abstract
Background: Wolfram Syndrome (WS) is an autosomal recessive neurodegenerative disorder characterized by Diabetes
Insipidus, Diabetes Mellitus, Optic Atrophy, and Deafness identified by the acronym ‘‘DIDMOAD’’. The WS gene, WFS1,
encodes a transmembrane protein called Wolframin, which recent evidence suggests may serve as a novel endoplasmic
reticulum calcium channel in pancreatic b-cells and neurons. WS is a rare disease, with an estimated prevalence of 1/550.000
children, with a carrier frequency of 1/354. The aim of our study was to determine the genotype of WS patients in order to
establish a genotype/phenotype correlation.
Methodology/Principal Findings: We clinically evaluated 9 young patients from 9 unrelated families (6 males, 3 females).
Basic criteria for WS clinical diagnosis were coexistence of insulin-treated diabetes mellitus and optic atrophy occurring
before 15 years of age. Genetic analysis for WFS1 was performed by direct sequencing. Molecular sequencing revealed 5
heterozygous compound and 3 homozygous mutations. All of them were located in exon 8, except one in exon 4. In one
proband only an heterozygous mutation (A684V) was found. Two new variants c.2663 C.A and c.1381 A.C were detected.
Conclusions/Significance: Our study increases the spectrum of WFS1 mutations with two novel variants. The male patient
carrying the compound mutation [c.1060_1062delTTC]+[c.2663 C.A] showed the most severe phenotype: diabetes
mellitus, optic atrophy (visual acuity 5/10), deafness with deep auditory bilaterally 8000 Hz, diabetes insipidus associated to
reduced volume of posterior pituitary and pons. He died in bed at the age of 13 years. The other patient carrying the
compound mutation [c.409_424dup16]+[c.1381 A.C] showed a less severe phenotype (DM, OA).
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Introduction
Wolfram Syndrome (WS), also known as DIDMOAD
(Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy and
Deafness), is an autosomal recessive neurodegenerative disease
usually diagnosed in childhood when non autoimmune diabetes
occurs with optic atrophy [1,2]. The condition is very rare with
an estimated prevalence of one in 550.000 of children, [3] and
with a carrier frequency of one in 354. Mortality is ,65% before
age 35 years, due to central respiratory failure with brainstem
atrophy and renal failure secondary to infections [4]. Recently
WS was described in a 44 year old patient with diabetes mellitus,
central respiratory failure, cognitive impairment, ataxia and
parkinsonism [5].
The nuclear gene for WS, WFS1, mapped on chromosome
4p16.1 [6], is composed of eight exons: the first is noncoding, the
2
nd to the 7
th are coding exons, and the 8
th is 2.6 kb long
spanning 33.4 kb of genomic DNA. The 3.6-kb mRNA encodes
an 890-aminoacid hydrophobic and tetrameric protein named
Wolframin [7], composed by nine transmembrane segments and
large hydrophilic regions at both termini [8]. WFS1 mRNA is
expressed in pancreas, brain, heart, skeletal muscle, placenta,
lung, liver and kidney. Biochemical studies in cultured cells
indicate WFS1 to be an integral, endoglycosidase H-sensitive
membrane glycoprotein that primarily localizes in the endoplas-
mic reticulum. Evidence suggests that WFS1 is either a novel
endoplasmic reticulum calcium channel or a regulator of channel
activity [9,10].
In 2000 a second locus, WFS2, has been mapped on
chromosome 4q22-q24 following the linkage analysis of four
consanguineous Jordanian families [11]. These patients were not
affected by diabetes insipidus, but showed upper gastrointestinal
ulceration and bleeding. The ZCD2-encoded protein, ERIS
(Endoplasmic Reticulum Intermembrane Small protein), is also
shown to localize to the endoplasmic reticulum but does not
interact directly with Wolframin.
The aim of our study was to evaluate clinical and molecular
observations in nine patients with WS from nine different families
and their follow-up in order to establish a genotype/phenotype
correlation.
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Etical Statement
The research was conducted according to Declaration of
Helsinki and approved by IRCCS Giannina Gaslini Institute
Ethical Committee.
Subjects
We clinically evaluated nine unrelated patients (six males and
three females) from nine unrelated families, referred to our
Pediatric Clinic. Basic criteria for the Wolfram Syndrome
diagnosis were the coexistence of insulin-treated, juvenile-onset
Diabetes Mellitus (DM) and Optic Atrophy (OA) occurring before
15 years of age. All analyses were performed after informed
written consent obtained from patients or their parents.
Biochemical and clinical analyses
Autoantibodies against pancreatic b-cells (anti-glutamic acid
decarboxylase: GADA, anti-thyrosin phosphatase-like protein: IA-
2A, anti-insulin: IAA) were detected by RIA [12], and the analysis
of HLA-DQA1 and -DQB1 polymorphisms at genomic levels was
performed by polymerase chain reaction/sequence specific
primers technique [13]. OA was confirmed by the presence of
white papilla with regular and well-demarcated borders at the
ophthalmoscope. As regards microangiopathic complications,
peripheral neuropathy was assessed by electrophysiological
examination, retinopathy was detected by fundoscopy and
nephropathy screening was performed by overnight albumin
excretion rate. Brain nuclear magnetic resonance (NMR) imaging
was performed to assess posterior pituitary and brain structures.
Structural renal tract abnormalities were assessed by ultrasonog-
raphy and intravenous urography. Diagnosis of Diabetes Insipidus
(DI) was based on the clinical findings of polyuria, polydipsia, an
osmolality of less than 300 mOsm per kilogram of water, or a
specific gravity of less than 1010 in a 24 hour urine sample without
glycosuria and ketonuria [14]. Hearing impairment was assessed
by audiograms across a range of frequencies (125–8000 Hz), and
by brainstem auditory evoked potentials to explore the central
conduction time of the auditory pathways.
Molecular analyses
DNA from probands, parents and controls were extracted from
whole blood using High Pure PCR Template Preparation Kit
(Roche, Mannheim, Germany). Exons and flanking regions of
WFS1 were amplified by PCR using previously described primers
[15]. Amplicons were purified with exonuclease I and shrimp
alkaline phosphatase (ExoSap-IT, USB Corporation, Staufen,
Germany) and then sequenced for both sense and antisense
strands using an automated fluorescent sequencing method (Big
Dye Terminator Kit v1.1, Applied Biosystems). The products were
separated on a ABI PRISM sequencing apparatus 3730 (Applied
Biosystems). All variation were validated by sequencing both DNA
strand of three independent PCR products.
Results
Main clinical data of each our patients are reported in Table 1.
Mutational screening, conducted in our Laboratory, revealed a
total of 14 distinct variants (7 missense, 2 nonsense, 5 frameshift) all
located in exon8 except the c. 409_424dup16 inexon 4. Twelve were
already described (c.1628T.G, c.2104 G.A, c.1060_1062delTTC,
c.1620delGTG, c.2020 G.A, c.1885C.T, c.1230_1233delCTCT,
c.1582 T.G, c.2106_2113del8n, c.2051C.T, c.1456 C.T,
c.409_424dup16) [15,16,17,15,18,19,20,21,21–22,23,15,24] and
two: the c.2663 C.A, p. S888X; and the c.1381 A.C, p. T461P
were novel (Table 2). In order to establish the correct allelic
segregation, DNA of parents were sequenced in all cases except in
parents of proband 7, whose DNA sample was not available when
molecular investigation was performed. None WFS1 mutations
was found in the 100 normal unrelated controls screened by
sequencing. None of these mutations has been described in our
previous work [25].
Case 1
A male patient, with surgically repaired Tetralogy of Fallot at
age of 3 years, received a diagnosis of OA and DM without
ketoacidosis at the age of 10 and 11 years respectively. B-cells
autoantibodies were absent. Molecular analysis of HLA-DR and
HLA-DQ regions revealed 0 heterodimers for type 1 DM
susceptibility. He had a sudden anxiety with psychotic hints.
The patient carried compound heterozygous mutation: the
c.1628T.G, leading to substitution of Leucine with Arginine at
codon 543 (L543R), this amino acid change was located in the
sixth transmembrane domain of Wolframin. The G702S caused
by G.A transition at nucleotide 2104, resulting in the substitution
of Glycine with Serine at codon 702.
Table 1. Clinical features and age at diagnosis in nine patients with Wolfram Syndrome.
Patient n6 Sex (M/F)
Current Age
(years)
DM
(age)
OA
(age)
DI
(age)
D
(age)
Renal tract
abnormalities Neurologic abnormalities
1 M 23 11 10 - - - Anxiety with psychotic hints
2M 1 3 4 9 K 9 K 9 K - Reduced volume of posterior pituitary
3 M 15 11 14 - - - -
4 F 1 2 99- - - -
5 M 17 10 7 16 16 - -
6 F 12 7 11 - - double left district -
7 F 15 14 14 - 10 months - Mild cognitive impairment
8 M 1 2 4677 - P o s t e r i o r p i t u i t a r y a b s e n c e
9M 1 7 9 1 6 - - - -
(Patient nu 2 suddenly died at the age of 13 years).
DM: diabetes mellitus; OA: optic atrophy; DI: diabetes insipidus; D: deafness.
Current age: 2011.
doi:10.1371/journal.pone.0029150.t001
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A male patient with the most severe phenotype, died in bed at
the age of 13 years. He showed DM with glycosuria, chetonuria, in
absence of ketoacidosis at age of 4 years. B-cells autoantibodies
were absent. Molecular analysis of HLA-DR and HLA-DQ
regions revealed 0 heterodimers of susceptibility for type 1 DM.
Celiac disease was diagnosed at age of 8 years and gluten free diet
was prescribed. At age of 9 years he started to suffer from
nocturnal apnea. OA (visual acuity 5/10) was diagnosed by
fundoscopy at age of 9.5 years. Brain NMR revealed reducing the
volume of posterior pituitary and optic nerve atrophy. Also DI and
deafness (D) with hearing impairment at the 8000 Hz bilaterally
were diagnosed at the age of 9.5 years. He harbored in-frame 3-bp
deletion, nucleotides 1060_1062, in exon 8, that results in the loss
of Phenylalanine 354 residue. According to the predicted structure
of the Wolframin protein [17] residues 350 and 354 are likely to be
located in the first transmembrane domain. However, the ultimate
effect of these deletions cannot be anticipated yet. He also carried
a novel nonsense mutation in exon 8 c.2663 C.A leading to
S888X, causing a premature stop codon at residue 888 which
removes 2 high conserved aminoacids from the carboxy tail.
Case 3
A male patient developed insulin treated DM without
ketoacidosis at 11 years of age. B-cells autoantibodies were absent.
Molecular analysis of HLA-DR and HLA-DQ regions revealed 0
heterodimers for type 1 DM susceptibility. OA was diagnosed at
the age of 14 years. DI and D were absent up to now. He harbored
an in-frame deletion, 1620delGTG, causing the loss of one Valine
residue (V540del) and a missense mutation G674R resulting in the
substitution of Glycine with Arginine at codon 674.
Case 4
A female patient developed insulin-treated DM and OA at the
age of 9 years. B-cells autoantibodies were absent. Molecular
analysis of HLA-DR and HLA-DQ regions revealed 0 heterodi-
mers of susceptibility for type 1 DM. DI and D were not present
up to now. She was found to be compound heterozygous: the
R629W that converted Arginine in Tryptophan at codon 629 and
the in-frame deletion of four nucleotides at position 1230 resulting
in a premature stop codon, predicting a truncated protein of 450
aminoacids (V412fsX440).
Case 5
A male patient presented at the age of 7 years impaired vision,
mild papillary pallor, presence some microaneurysms at fundos-
copy, diffuse reduction of sensitivity: genetic testing for Leber’s
optic atrophy was positive. He suffered from insulin-treated DM
with glycosuria, chetonuria, ketoacidosis since the age of 10 years.
B-cells autoantibodies were absent. Molecular analysis of HLA-
DR and HLA-DQ regions revealed 1 heterodimer for type 1 DM
susceptibility. At the age of 16 years D with loss of sensorineural
hearing for high tones, confirmed by audiometric test, and DI
were diagnosed. He carried a homozygous missense mutation,
inherited from both his parents, c.1582 T.G resulting in the
substitution of Tyrosine with Aspartic Acid at codon 528 (Y528D).
Case 6
A female patient developed insulin treated DM at 7 years of age.
B-cells autoantibodies were absent. Molecular analysis of HLA-
DR and HLA-DQ regions revealed 2 heterodimers for type 1 DM
susceptibility. At the age of 11, OA was diagnosed by fundoscopy;
brain NMR signs of optic nerve impairment. DI, D were absent up
to now. Urinary tract ultrasonography showed a double left
district. She was found to have a homozygous 8-bp deletion from
both alleles, nucleotides 2106_2113 in exon 8, resulting in a
frameshift at codon 646 (Phenylalanine) and an early STOP
codon, predicting a truncated protein of 708 amino acids missing
part of the transmembrane domains and its hydrophilic carboxy
tail.
Case 7
A female patient had profound deafness from the age of 10
months confirmed by audiometric test; at age of 5 years a cochlear
Table 2. Mutations in the WFS1 gene (new identified WFS1 mutations are presented in bold).
Family Exon Nucleotide change
Amino acide
change Type of mutation Reference
1 8 c.1628T.G; L543R; Missense; Colosimo et al.[2003]
c.2104 G.A G702S missense Gasparin et al. [2009]
2 8 c.1060_1062delTTC; F354del; Frameshift; Hardy et al. [1999]
c.2663 C.A S888X nonsense This study
3 8 c.1620delGTG; V540del; Frameshift; Colosimo et al.[2003]
c.2020G.A G674R missense Khanim et al. [2001]
4 8 c.1885C.T; R629W; Missense; Kadayifci et al.[2001]
c.1230_1233delCTCT V412fsX440 frameshift; Giuliano et al. [2005]
5 8 c.1582 T.G Y528D Missense Zalloua et al. [2008]
6 8 c.2106_2113del8nt F646fs708X Frameshift Zalloua et al. [2008]
Rigoli et al. [2011]
7 8 c.2051 C.T A684V Missense Tessa et al. [2001]
8 8 c.1456 C.T Q486X Nonsense Colosimo et al.[2003]
9 4 c. 409_424dup16 V142fsX251 Frameshift; Gomez-Zaera et al. [2001]
8 c.1381 A.C T461P missense This study
(Patient 7 carried only one heterozygous mutation).
doi:10.1371/journal.pone.0029150.t002
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glycosuria, chetonuria, ketoacidosis, and OA at 14 years of age.
B-cells autoantibodies were absent. Molecular analysis of HLA-
DR and HLA-DQ regions revealed 0 heterodimers of suscepti-
bility for type 1 DM. DI is absent up to now. She showed mild
cognitive impairment. Only one heterozygous mutation was
found: the A684V caused by C.T transition at nucleotide 2051
resulting in the substitution of Alanine with Valine at codon 684.
She also carried 10 polymorphisms (rs1801213 CG Het,
rs1801212 AG Het, rs1801206 CT Het [V395V associated with
DM1[26]], rs1801208 GA Het [R456H, associated with risk of
Type 2 Diabetes [27], suicide [28] non autoimmune Diabetes
[29]] rs1801214 CT Het, rs1046314 AG Het and rs1046316 AG
Het [K811K and S855S, associated with DM1 [26]], rs1046317
CT Het, rs1046319 CT Het, rs1802453 GA Het). The A684V
could not be confirmed in her parents since no DNA sample from
their was available at the time of the screening of WFS1 gene.
Case 8
A male patient showed all the clinical features of the syndrome:
he suffered from insulin-treated DM since the age of 4. B-cells
autoantibodies were absent. Molecular analysis of HLA-DR and
HLA-DQ regions revealed 0 heterodimers for type 1 DM
susceptibility. At the age of 6 years, OA was found and at age of
7 years, bilateral sensoneurial deafness and DI were diagnosed.
Brain NMR revealed reducing the thickness of the nerve and
chiasm and optic tracts, a nodule of heterotopic gray matter in the
left anterior frontal periventricular. The posterior pituitary was not
present. He resulted to be homozygous for the nonsense mutation
1456 C.T leading to a premature stop codon at residue 468
(Q486X), inherited from both his parents. This variant is predicted
to give rise to an abnormal protein, missing part of the
transmembrane domains and its hydrophilic carboxy tail.
Case 9
A male patient suffered from insulin-treated DM since the age
of 9 years. Autoantibodies against b-cells were absent. Molecular
analysis of HLA-DR and HLA-DQ regions revealed 0 heterodi-
mers for type 1 DM susceptibility. At the age of 16 years OA was
diagnosed. DI and D were absent up to now. He carried a
compound heterozygous mutation: the 409_424dup16 in exon 4 is
predicted to produce an aberrant protein; assuming that no
splicing alterations occur, translation will follow until residue 251,
where a stop codon is created [24]. The other identified change
was a novel missense mutation c.1381 A.C resulting in the
substitution of Treonine with Proline at codon 461.
Discussion
We report clinical and molecular observations about nine
unrelated patients with WS and their follow-up. Up to now a wide
spectrum of WFS1 mutations were described [22]. In our study 14
different molecular defects were found. Thirteen were identified in
both alleles: five probands carried compound heterozygous for
WFS1 mutations; three had WFS1 defects in homozygous state. In
one proband (patient 7) only an heterozygous mutation (A684V)
was detected. Two novel mutations the S888X, and the T461P
were found in patients 2 and 9 respectively (Table 2). All cases
exhibited the main clinical features of WS.
The median age of the patients at the time of DNA analysis was
15,1 years (range 12–23).
Diabetes Mellitus is usually the first symptom occurring before
age of 10 years, with optic atrophy at a median age of 11 years
[30]. In our series, the average age at onset of diabetes was 8,7
years (range 4–14). WS-associated DM shows clear differences
respect to autoimmune type 1 diabetes. WS-associated DM is due
to loss of pancreatic b-cell function and number, as confirmed by
autoptic studies, without markers for an autoimmune process [31].
Optic Atrophy occurs by definition in all patients with WS
and is progressive. All our patients had OA and its identification
was concomitant or after diabetes diagnosis except in case nu 1
and 5: where OA occurred before DM diagnosis. OA was
diagnosed and confirmed by brain NMR in the first decade of
life in 5 cases and between 11 and 16 years of age in the other 4.
Although our patients are genetically heterogeneous, ophthal-
mological findings and age at detection are similar to other series
[4,32,33]. The pathogenesis of OA could result from the effects
of WS mutation on the survival of retinal ganglion cells, and in
that case the mutation would lead to anterograde atrophy of
retinal axons and shrinkage of the optic nerve. Retinal ganglion
cells and optic nerve glial cells were found to be strongly
labelled, suggesting that dual dysfunction of Wolframin in these
cells might explain the progressive optic nerve atrophy reported
in WS [34].
The development of polyuria and/or enuresis can indicate
diabetes insipidus, which usually appears during the second
decade. In our series only three patients showed DI at younger
age (nu 2, 5, 8 at age of 91/2, 16, 7 years respectively). (Table 1).
Sensorineural Deafness, confirmed by audiograms, was
diagnosed in three patients at a mean age of 10.8 years (range
7–91/2). Proband 7 had profound deafness from infancy
requiring a cochlear implant. Such early onset of severe deafness
has not been usually reported in Wolfram Syndrome. Hearing
impairment reported in 66% of WS patients, ranging from
congenital deafness to mild, progressive hearing impairment.
Other case series reported deafness at a median age of 16 years
in 60% of cases [35]. Audiometric features include a severe
auditory threshold shift, more evident for the medium/high
frequencies. Auditory impairment could be a consequence not
only of a dysfunction of cochlear neurons and VII nerve fibers,
but also of the central nervous pathways in brainstem and
inferior colliculus [36].
Involvement of urinary tract represents another serious
complication in WS patients and is estimated to occur in up to
90% of patients, being diagnosed during adolescence [37] or
adulthood [38]. In our cases has been found only one patient (nu 6)
with renal tract abnormalities: the ultrasonography of the urinary
tract showed a double left district.
Neuropsychiatric manifestations are reported in the third
decade. However Chaussenot A et al, who showed that the onset
of neurologic symptoms, with a median age of 15 years, is much
earlier than previously reported (mean age 30 years) [39]. In the
majority of our patients behavioral problems or depression were
evident at much younger ages. This could be due to the fact that
previous studies focused on cerebellar ataxia and brainstem
involvement as main neurological involvement in WS.
In many cases, it can be difficult to tease out the effect of
multiple disabilities and reactive depression from a true depressive
illness. It is important to involve a pediatric psychiatrist as part of
the multidisciplinary team, particularly if there is a seminal event
such as a first seizure. Such events can have devastating
psychological consequences for an adolescent.
Wolframin in vivo is organized as a tetramer which originates a
membrane Ca
2+ channel of the Endoplasmic Reticulum (ER) and
lack of function of WFS1 determines apoptotic input signaling
[40]. The ER has many roles, which include post-translational
modification, folding and assembly of newly synthesized proteins
such as insulin. Perturbations in ER function cause an imbalance
Wolfram Syndrome: Novel Mutations
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unfolded proteins in +the organelle, a state called ER stress [41].
Except the V142fsX251 found in exon 4, all the detected
mutations are located in exon 8, corresponding to the
transmembrane region and carboxytail of Wolframin protein.
The majority of mutations described in our study were localized
to the predicted transmembrane domains (64,3%, n=9/14).
Mutations in the amino-terminal domain were identified on 1
(7,1%) and in the carboxy-tail on 4 (28,6%) respectively (Fig. 1).
This is in agreement with other studies in Italian and world-wide
populations [15]. All causative mutations were identified on both
alleles except in one case in which only one heterozygous
mutation was found.
The predicting information that genetic analysis can give
regards the difference between inactivating and non-inactivating
mutations. The age at onset of DM was chosen as an indicator of
disease severity. Missense mutations and 3 bp deletions, resulting
in a deletion of one amino acid, were considered non-inactivating
mutations. Nonsense, frameshift mutations, deletions and
insertions of more than 3 bp were considered inactivating
mutations [42]. Among the five patients with WFS1 compound
heterozygous mutation, two carried 2 non-inactivating muta-
tions, three carried 1 inactivating and 1 non-inactivating. Their
ages at diabetes clinical onset were 11 years and 7,3 years,
respectively.
Among the three patients with WFS1 homozygous mutation two
carried inactivating and one non-activating; their mean ages at
onset of diabetes were 5,5 and 10 years respectively.
Patient 7 carried only one non-inactivating mutation and the
age at onset of diabetes was 14 years.
However, the only patient harbouring one mutations outside
exon 8 showed a mild phenotype: the onset of diabetes mellitus
and optic atrophy was 9 and 16 years respectively. A hearing
deficit, diabetes insipidus, renal tract and neurologic abnormalities
were absent. We could observe in our study that inactivating
mutation give a more severe phenotype that non inactivating
mutation, although clinical symptoms are different, according to a
previous observation [9].
In our study, seven cases among 9 cases were identified
mutations already published elsewhere. To clarify the actual
genotype/phenotype correlation, we compared clinical manifes-
taions of the subjects sharing the same mutations. The clinical
features caused by the missense mutation Y528D and the delection
F646fs708X, both found in homozygous state in proband P5 and
in P6, respectively; were similar to what reported by Zalluoa 2008
and Zalluoa 2008-Rigoli 2011. Unfortunately, the combination of
compound heterozygous defects found in our series has never been
reported in literature. So, it is difficult to compare the phenotype
these our patients with what reported in other studies. However,
validation of any genotype–phenotype correlation must await
detailed functional analysis of mutations on a cellular and
molecular level.
If the mutation causing the syndrome in a family is known, it is
possible to offer genetic counselling and prenatal diagnosis.
Prenatal diagnosis is possible analyzing DNA extracted from fetal
cells by amniocentesis at approximately 15–18 weeks gestation or
chorionic villus sampling at approximately 10–12 weeks gestation.
[43,44].
WS is a progressive neurodegenerative disorder, that usually
appears in adolescence and requires careful endocrinological
evaluation aimed to start an early and adequate hormonal
substitutive therapy. Even if WS is characterized by a wide
differential diagnosis including other causes of neurodegenera-
tion, it should be suspected in a young with diabetes mellitus and
optic atrophy, hearing loss, polyuria and polydipsia but adequate
glucose control [44]. Genetic test represents the best opportunity
to confirm the clinical diagnosis and to propose prenatal
diagnosis.
In conclusion, we have analyzed the WFS1 in nine WS patients.
Our study increases the spectrum of WFS1 mutations with two
novel variants.
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